AMX-883 for Acute Myeloid Leukemia and Myelodysplastic Syndrome

(BRAMLIE Trial)

This trial tests a new treatment, AMX-883, for individuals with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The researchers aim to assess the safety and effectiveness of AMX-883, both alone and in combination with another drug, posaconazole. This trial targets those whose current treatments are ineffective and who often experience symptoms like fatigue or frequent infections. Participants will receive the treatment in various ways to determine the best approach. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.

The trial requires a 'washout period' (time without taking certain medications) from prior therapies, and you cannot take medications with a known risk of Torsades de Pointes unless they can be stopped before the study treatment. It's best to discuss your current medications with the trial team to see if any need to be paused.

Research shows that AMX-883 is a new treatment under investigation for its safety and effectiveness in treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The current trial is in an early phase, focusing primarily on ensuring the treatment's safety for people.

There is no specific data from earlier studies on AMX-883's effects in humans. However, the FDA has approved it for clinical testing, indicating it showed enough promise in lab studies to warrant testing in people. This approval marks an important step but does not guarantee safety; it means the treatment passed initial safety checks in the lab.

AMX-883 is being tested with posaconazole, a drug already used to prevent fungal infections in patients with conditions like AML and MDS. Posaconazole is well-known and generally well-tolerated, providing some reassurance about its safety.

Researchers are excited about AMX-883 for treating Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) because it offers a fresh approach compared to traditional chemotherapies like cytarabine and daunorubicin. AMX-883 is unique because it’s being tested both as a monotherapy and in combination with posaconazole, which might enhance its effectiveness against cancer cells. Additionally, the trial explores how different doses and food intake affect the drug’s performance, aiming to optimize its use. This innovative angle could lead to more personalized and potentially more effective treatment options for patients with AML and MDS.

This trial will evaluate AMX-883 for treating acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Participants in one arm of the trial will receive AMX-883 combined with posaconazole. Research suggests that this combination might help treat these conditions. Studies have shown that posaconazole, an antifungal medicine, effectively prevents fungal infections in patients with weakened immune systems, such as those receiving AML treatment. This combination aims to improve treatment by potentially reducing infection-related complications. Although information on AMX-883 alone is limited, its combination with posaconazole appears promising due to posaconazole's known benefits. The specific effectiveness of AMX-883 is still under study, with early research exploring its potential synergy with other treatments.⁶⁷⁸⁹¹⁰